8-K: KORU Medical Systems Reports Double-Digit Revenue Growth in First Quarter 2024

KORU Medical Systems announced a strong start to 2024 with an 11% increase in first-quarter revenue and a new oncology collaboration.

Summary

• KORU Medical Systems reported a 10.9% increase in total net revenue, reaching $8.2 million for the first quarter of 2024, compared to $7.4 million in the same period of 2023.
• The company's core business, encompassing both domestic and international sales, grew by 13.6%, with international core revenue experiencing a significant 63.1% increase.
• Novel Therapies revenue decreased by 21.3% due to a milestone completion in the prior year.
• Gross profit increased by 23% to $5.1 million, with a gross margin of 62.3%, up from 56.1% in the first quarter of 2023.
• The company's net loss for the quarter was $1.9 million, or $(0.04) per diluted share, an improvement from a net loss of $2.4 million, or ($0.05) per diluted share, in the same period last year.
• Adjusted EBITDA was ($0.9) million, or ($0.02) per diluted share, compared to ($2.0) million, or ($0.04) per diluted share, for the same period in 2023.
• KORU Medical reaffirmed its full-year 2024 revenue guidance of $31.2 million to $32.2 million, representing growth of 10% to 13% over the prior year.
• The company ended the quarter with a cash balance of $10.8 million and used $0.7 million in cash during the quarter.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved gross margins, and reaffirmed guidance. While there are some losses, the overall trend is positive, and management expresses confidence in future performance.

Positives

• The company experienced double-digit revenue growth in the first quarter of 2024.
• International core revenue saw a substantial increase of 63.1%.
• Gross margin improved significantly to 62.3%, driven by production efficiencies.
• Cash usage decreased to $0.7 million for the quarter, indicating improved financial management.
• The company reaffirmed its full-year revenue guidance, showing confidence in future performance.
• KORU Medical added a new oncology collaboration, expanding its Novel Therapies business.

Negatives

• Novel Therapies revenue declined by 21.3% due to a milestone completion in the prior year.
• The company reported a net loss of $1.9 million for the quarter, although this is an improvement from the previous year.
• Adjusted EBITDA was negative at ($0.9) million, although this is an improvement from the previous year.

Risks

• The company faces uncertainties associated with SCIg market growth, prefilled syringe penetration, and plasma supply.
• Clinical trial activity and success, as well as the company's EU certification, pose potential risks.
• The shift to increased healthcare delivery in the home, new patient diagnoses, and customer ordering patterns could impact results.
• Global health crises, innovation and competition, labor and supply price increases, and inflationary impacts are also potential risks.
• The company's annual report on Form 10-K includes additional risk factors.

Future Outlook

KORU Medical reaffirmed its full-year 2024 net revenue guidance of $31.2 million to $32.2 million, representing growth of 10% to 13%. The company also expects a gross margin between 59% and 61% for the full year, a year-end cash balance greater than $8.0 million, and cash flow breakeven in the fourth quarter of 2024 and cash flow positive for full year 2025.

Management Comments

• Linda Tharby, KORU Medical's President and CEO, stated that they are excited by a strong start to the year with double-digit record revenue growth in their Core business and the addition of a new oncology collaboration.
• Management is committed to their strategic growth agenda and providing increased value to their customers, patients, and shareholders.

Industry Context

The announcement reflects a positive trend in the medical technology sector, particularly in the subcutaneous infusion market. The company's growth is driven by increased adoption of its products and expansion into new geographic areas. The addition of a new oncology collaboration also indicates a strategic move to diversify its drug pipeline.

Comparison to Industry Standards

• KORU Medical's 11% revenue growth is strong compared to the broader medical device industry, which has seen moderate growth in recent quarters.
• The 62.3% gross margin is competitive, indicating efficient operations and cost management, although specific benchmarks vary widely across the medical device sector.
• Companies like Insulet (PODD) and Tandem Diabetes Care (TNDM), which focus on diabetes management, have seen similar growth in their respective markets, but KORU's focus on subcutaneous infusion for other therapies provides a unique market position.
• The company's focus on home healthcare aligns with a broader industry trend towards decentralized care, which is expected to drive future growth.

Stakeholder Impact

• Shareholders will likely view the results positively due to the revenue growth and improved financial metrics.
• Patients will benefit from the company's focus on innovative and patient-centric solutions.
• Employees may experience increased job security and opportunities due to the company's growth.
• Customers will benefit from the company's continued investment in product development and expansion.

Next Steps

• The company will host a conference call and webcast on May 1, 2024, to discuss the results and provide a corporate update.
• KORU Medical will continue to focus on its strategic growth agenda and expanding its market presence.

Key Dates

Keywords

KORU Medical, Subcutaneous Infusion, Medical Technology, Revenue Growth, Gross Margin, Adjusted EBITDA, Novel Therapies, SCIg, Financial Results, Healthcare